AptarGroup (ATR) Q4 2024 earnings summary

Executive summary

• Achieved 3% reported and core sales growth in 2024, reaching $3.6B in annual sales, with Q4 core sales up 2% and strong operational performance, driven by pharma and closures segments.

• Net income rose 32% to $375M for the year, with Q4 net income up 62% to $101M; adjusted EPS for Q4 was $1.52, up 27% year-over-year.

• Achieved double-digit EPS growth for the second consecutive year, with margin expansion in pharma and closures.

• 2024 marked the 31st consecutive year of increasing annual dividends.

Financial highlights

• Q4 2024 reported sales: $848M (+1% year-over-year); adjusted EBITDA: $195M (+9%), margin 23%.

• Full-year 2024 reported sales: $3.58B (+3%); adjusted EBITDA: $775M (21.6% margin, up from 20.3% in 2023).

• Full-year adjusted EPS: $5.64 (+18%); Q4 adjusted EPS: $1.52 (+27%).

• Net cash from operations increased 12% to $643M; free cash flow up 40% to $367M.

• Effective tax rate for Q4 was 13% (down from 23%); full-year rate was 20%.

Outlook and guidance

• Q1 2025 adjusted EPS expected in the range of $1.11–$1.19, with a 7% currency headwind and higher tax rate (25–27%).

• 2025 is expected to deliver solid earnings growth, led by pharma and proprietary drug delivery systems, despite significant FX and tax headwinds.

• Anticipates about a 15% combined impact from currency and tax in Q1, with softer demand in prestige fragrance/skincare and nasal saline, but healthy demand in higher value pharma products.

• Capital expenditures for 2025 expected at $280–$300M, mostly allocated to pharma.